- Home
- DBVT vs CATX Comparison
DBVT vs CATX Comparison
Compare DBVT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- CATX
- Stock Information
- Founded
- DBVT 2002
- CATX 1983
- Country
- DBVT France
- CATX United States
- Employees
- DBVT N/A
- CATX N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- CATX Medical/Dental Instruments
- Sector
- DBVT Health Care
- CATX Health Care
- Exchange
- DBVT Nasdaq
- CATX Nasdaq
- Market Cap
- DBVT 260.5M
- CATX 239.0M
- IPO Year
- DBVT N/A
- CATX N/A
- Fundamental
- Price
- DBVT $15.48
- CATX $3.87
- Analyst Decision
- DBVT Buy
- CATX Strong Buy
- Analyst Count
- DBVT 4
- CATX 10
- Target Price
- DBVT $14.81
- CATX $12.90
- AVG Volume (30 Days)
- DBVT 94.7K
- CATX 835.6K
- Earning Date
- DBVT 11-05-2025
- CATX 11-11-2025
- Dividend Yield
- DBVT N/A
- CATX N/A
- EPS Growth
- DBVT N/A
- CATX N/A
- EPS
- DBVT N/A
- CATX N/A
- Revenue
- DBVT $3,800,000.00
- CATX $1,235,000.00
- Revenue This Year
- DBVT $1,743.46
- CATX N/A
- Revenue Next Year
- DBVT $1,044.34
- CATX N/A
- P/E Ratio
- DBVT N/A
- CATX N/A
- Revenue Growth
- DBVT N/A
- CATX N/A
- 52 Week Low
- DBVT $2.21
- CATX $1.60
- 52 Week High
- DBVT $15.95
- CATX $13.44
- Technical
- Relative Strength Index (RSI)
- DBVT 87.03
- CATX 53.74
- Support Level
- DBVT $9.19
- CATX $3.37
- Resistance Level
- DBVT $14.44
- CATX $3.78
- Average True Range (ATR)
- DBVT 0.84
- CATX 0.20
- MACD
- DBVT 0.64
- CATX 0.04
- Stochastic Oscillator
- DBVT 100.00
- CATX 66.14
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.